After a competitive bidding process, MorphoSys AG has struck a development and commercialization deal with GlaxoSmithKline PLC for its mid-stage rheumatoid arthritis antibody. The German company has been searching for a partner to bring the asset forward after early data presented in September showed clinical activity within four weeks.
The deal, announced June 3, gives MorphoSys near-term cash in the form of a €22.5 million ($29.5 million) upfront, plus...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?